NCT07092410 2026-04-21
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Withdrawn
Clinical Trials
11 trialsNCT05026983 2026-04-16
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07022457 2026-04-13
UK-EnBiRiM
Pierre Fabre Ltd
Active not recruiting
NCT04657991 2026-04-07
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT04221438 2026-04-01
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT04903119 2026-02-13
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Phase 1 Recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting